Provided by Tiger Fintech (Singapore) Pte. Ltd.

Keros Therapeutics, Inc.

14.07
+0.54003.99%
Post-market: 14.05-0.0200-0.14%19:47 EDT
Volume:1.35M
Turnover:18.88M
Market Cap:570.71M
PE:-2.81
High:14.20
Open:13.42
Low:13.42
Close:13.53
Loading ...

BRIEF-Keros Therapeutics Announces Effectiveness Of Global License Agreement With Takeda

Reuters
·
21 Jan

Cantor Fitzgerald Downgrades Keros Therapeutics to Neutral From Overweight

MT Newswires Live
·
21 Jan

Keros Therapeutics Inc - Takeda to Make $200 Million Upfront Payment to Co in Connection With Effectiveness of Agreement

THOMSON REUTERS
·
21 Jan

Keros Therapeutics Announces Effectiveness of Global License Agreement With Takeda to Advance Elritercept

THOMSON REUTERS
·
21 Jan

Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept

GlobeNewswire
·
21 Jan

Wedbush Downgrades Keros Therapeutics to Neutral From Outperform

MT Newswires Live
·
18 Jan

Keros Therapeutics Inc : Wedbush Cuts to Neutral From Outperform; Cuts Target Price to $15 From $47

THOMSON REUTERS
·
18 Jan

Keros Therapeutics (KROS) Gets a Buy from Piper Sandler

TIPRANKS
·
17 Jan

U.S. RESEARCH ROUNDUP- Hubspot, Morgan Stanley, US Bancorp

Reuters
·
17 Jan

Keros Therapeutics Inc : Piper Sandler Cuts Target Price to $15 From $40

THOMSON REUTERS
·
17 Jan

Keros Therapeutics Is Maintained at Sector Outperform by Scotiabank

Dow Jones
·
17 Jan

Here's Why Keros Therapeutics (KROS) is Poised for a Turnaround After Losing -39.17% in 4 Weeks

Zacks
·
16 Jan

Keros Therapeutics Inc. : Oppenheimer Cuts Target Price to $23 From $63

THOMSON REUTERS
·
16 Jan

Truist Financial Gives a Buy Rating to Keros Therapeutics (KROS)

TIPRANKS
·
16 Jan

Keros Therapeutics Shares Down 13.2% After Co Halts Mid-Stage Blood Pressure Drug Trial

THOMSON REUTERS
·
15 Jan

Keros Therapeutics Shares Down After Halting Pulmonary Hypertension Treatment Trials

Dow Jones
·
15 Jan

Keros Therapeutics Inc : Scotiabank Cuts Target Price to $41 From $44

THOMSON REUTERS
·
15 Jan

Sector Update: Health Care Stocks Rise Premarket Wednesday

MT Newswires Live
·
15 Jan

Keros Therapeutics Voluntarily Halts Phase 2 Trial for Cibotercept Over Pericardial Effusion Concerns; Shares Drop Pre-Bell

MT Newswires Live
·
15 Jan

BRIEF-Keros Therapeutics Announces Additional Update On The Phase 2 Tropos Trial

Reuters
·
15 Jan